Igor Rudychev

The objective of this analysis was to evaluate persistence on and adherence to crizotinib using US pharmacy records.
De-identified records from five closed-distribution US specialty pharmacies supplying crizotinib in the 50 states and US territories were analyzed. Patients with at least one record of a shipped crizotinib prescription between 8/30/2011 and 8/1/2014 were eligible. Persistence − duration of time from initiation to discontinuation of therapy − was defined as the total number of… Mehr zeigen

The objective of this analysis was to evaluate persistence on and adherence to crizotinib using US pharmacy records.
De-identified records from five closed-distribution US specialty pharmacies supplying crizotinib in the 50 states and US territories were analyzed. Patients with at least one record of a shipped crizotinib prescription between 8/30/2011 and 8/1/2014 were eligible. Persistence − duration of time from initiation to discontinuation of therapy − was defined as the total number of days between the first and last prescription shipment dates plus the days' supply of the last prescription. Adherence − the extent to which a patient acts in accordance with the prescribed regimen − was evaluated using a medication possession ratio (MPR): the ratio of the total days' supply over the entire duration of therapy for patients with at least two crizotinib prescriptions.
Results:
A total of 3845 crizotinib patients were identified and included in the analysis. Most were commercially insured (69%), <65 years of age (61%), and female (56%). The cohort was well balanced geographically. Most prescriptions (89%) were for doses of 250 mg BID. Average duration of therapy was 11.4 months (95% CI: 11.2−11.6), with a median of 7.5 months. 51% and 34% of patients remained on therapy at 6 and 12 months, respectively. 16% of patients remained on crizotinib >24 months (Figure 1). Figure 1 An average MPR of 95% was observed in the sub-cohort of 3072 patients with two or more prescriptions of crizotinib. Sensitivity analyses revealed that persistence (11.2−11.6 months) and adherence (93−96%) estimates were not impacted by the alternative grace-period definitions applied.
In the real-world setting, the duration of crizotinib therapy was similar to that reported in clinical trials. Adherence to crizotinib was high and may be indicative of its acceptable tolerability. Further research is warranted to evaluate experiences associated with crizotinib using other real-world data sources. Weniger anzeigen

In this study we developed a novel approach to identify top physicians by Line of Therapy and to measure individual physician market shares in oral/biologics markets by Line of Therapy. We also identified high share IV physicians and compared their treatment patterns with the patterns of high share SubQ physicians.

This approach allowed us to optimize targeting by identifying physicians who use our product predominantly on 3rd and 4th lines of therapy and compare them with the 1st & 2nd… Mehr zeigen

In this study we developed a novel approach to identify top physicians by Line of Therapy and to measure individual physician market shares in oral/biologics markets by Line of Therapy. We also identified high share IV physicians and compared their treatment patterns with the patterns of high share SubQ physicians.

This approach allowed us to optimize targeting by identifying physicians who use our product predominantly on 3rd and 4th lines of therapy and compare them with the 1st & 2nd line physicians. It also explained low usage of SubQ products for IV dominant physicians.

The results of the analysis were used for targeting, segmentation, and sales force optimization. Potential targets for the promotional campaigns were identified. Physician segments by Line of Therapy, market shares, SubQ/IV dominance were created. Overlap of the top physicians who used our product as a 1st line with the influencers/decision makers allowed us to identified strong advocates for our product. Weniger anzeigen

Background: IM (Glivec, Gleevec) is an oral targeted therapy with unprecedented efficacy in CML and GIST. Prescription compliance and persistency of pts receiving IM were measured by analysis of pt-level pharmacy claims data. Methods: Compliance and persistency were determined by analyzing the prescription-filling activity of pts (N=4043) compared with the prescribing activity of their physicians (N=3316) using pt pharmacy records accrued over 24 months (1/03–12/04). Observed average daily… Mehr zeigen

Background: IM (Glivec, Gleevec) is an oral targeted therapy with unprecedented efficacy in CML and GIST. Prescription compliance and persistency of pts receiving IM were measured by analysis of pt-level pharmacy claims data. Methods: Compliance and persistency were determined by analyzing the prescription-filling activity of pts (N=4043) compared with the prescribing activity of their physicians (N=3316) using pt pharmacy records accrued over 24 months (1/03–12/04). Observed average daily consumption (DACON) and average prescribed days of therapy were calculated and compared. Also, compliance and persistency were examined by pt demographics and initial IM dose prescribed. Results: Overall compliance (defined as medication possession ratio = apparent mg taken/mg prescribed) was 75%, with CML pts showing slightly greater compliance (78%) than GIST pts (73%). Fifty percent of pts were 100% compliant, the greatest compliance being found in pts initially treated with IM 300 or 400 mg/day (77%). Persistency (time on therapy without significant gaps in refills) averaged 255 days over 24 months. The most persistent pts were those initially given 300 or 400 mg/day (13.0 and 12.9 months, respectively). DACON was 400 mg/day for 65% of patients, but fluctuated above and below 400 mg/day in 18% and 17% of pts, respectively. Conclusions: This is the first assessment of pt compliance and persistency with prescribed IM therapy. Although less pronounced than with most other non-oncology products, suboptimal compliance and persistency with IM are a concern as doses <300–400 mg may result in plasma levels lower than needed to eliminate cancer cells. Patient support programs and improved communication on the importance of adhering to recommended dosing could potentially optimize outcome and further reduce risk of relapse and progression. Weniger anzeigen

Product samples are a crucial part of any pharmaceutical marketing effort, but tracking their use has long been a hit-and-miss process. But by adopting new methodologies using patient-level data, marketers are able to optimize the distribution of drug samples to physicians' offices. Jean-Patrick Tsang and Igor Rudychev attempt to take the guesswork out of sampling.

Samples are a crucial component in the pharmaceutical marketer's toolbox. They not only encourage physicians to initiate… Mehr zeigen

Product samples are a crucial part of any pharmaceutical marketing effort, but tracking their use has long been a hit-and-miss process. But by adopting new methodologies using patient-level data, marketers are able to optimize the distribution of drug samples to physicians' offices. Jean-Patrick Tsang and Igor Rudychev attempt to take the guesswork out of sampling.

Samples are a crucial component in the pharmaceutical marketer's toolbox. They not only encourage physicians to initiate patients on the therapy, but they also provide a convenient excuse for sales reps to get through to the physician, hence making detailing possible. Yet tracking of samples stops with the reps dropping … Weniger anzeigen

Great physician targets are not synonymous with high-vol­ume prescribers. There are many physicians who do not write many scripts but who exert significant influence on other physicians that do. Often, they are prominent figures but they may also be low key, and there are many of them. There is another breed of physician equally worthy of sales and market­ing attention: physicians who make referral decisions for the patient. Depending on which way the referral goes, this can translate into… Mehr zeigen

Great physician targets are not synonymous with high-vol­ume prescribers. There are many physicians who do not write many scripts but who exert significant influence on other physicians that do. Often, they are prominent figures but they may also be low key, and there are many of them. There is another breed of physician equally worthy of sales and market­ing attention: physicians who make referral decisions for the patient. Depending on which way the referral goes, this can translate into significant additional or missed revenues.

Whereas no one would challenge the wisdom of tapping into influencers and referring/referred-to physicians, actually tapping into this group has been arduous. For starters, such physicians are difficult to pin down. To accomplish this, mar­keters have essentially resorted to two techniques: (1) inter­views, primary research, and feeds from the sales force and (2) the culling of rosters such as hospital affiliation and group­ practice affiliation. In both cases, the picture is spotty and may fail to portray the dynamics at work within physician circles.

This paper takes an off-the-beaten-track approach to this formidable problem by deploying patient-level data. The idea is very simple: Just like a phone call between two people may flag a relationship between the two, a patient that moves from one physician to another may be a giveaway that there is some relationship between the two. Patient level data capture exactly that. In addition, this approach identifies and profiles influencers and referral networks, the various levels of influence involved, unofficial networks at work, and insightful group dynamics. Weniger anzeigen